Lomefloxacin
Based on 1 Customer Validation
Lomefloxacin (SC47111A) is an orally active difluoroquinolone antibiotic. Lomefloxacin prevents DNA supercoiling and replication by inhibiting bacterial topoisomerase II. Lomefloxacin induces ROS production and Apoptosis. Lomefloxacin has broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Lomefloxacin has anticancer effects against melanoma. Lomefloxacin can be used in the study of systemic bacterial infections (such as Salmonella typhimurium infections), skin and melanoma .
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.99%
- CAS. Nr.: 98079-51-7
- Formel: C17H19F2N3O3
- Molecular Weight:351.35
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Anti-Lung Cancer Compound Library
HY-L075
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Nephrotoxicity Compound Library
HY-L229
-
Lactylation Compound Library
HY-L249
Alle Antibiotic Isoform-spezifische Produkte anzeigen
MoreAlle Topoisomerase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Quinolone |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
410 μM
Compound: Lomefloxacin
|
Inhibition of human HeLa cell proliferation
Inhibition of human HeLa cell proliferation
|
[PMID: 19595598] |
| NIH3T3 | IC50 |
483 μM
Compound: Lomefloxacin
|
Inhibition of mouse NIH/3T3 cell proliferation by MTT assay
Inhibition of mouse NIH/3T3 cell proliferation by MTT assay
|
[PMID: 19595598] |
Lomefloxacin (1/4 to 2×MIC concentrations) rapidly reduces viable cell counts of Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, with no regrowth observed in all strains except P. aeruginosa[1].
Lomefloxacin exhibits MIC values ranging from 0.06-4 μg/mL in susceptibility determination experiments with strains such as Escherichia coli and Staphylococcus aureus[2].
Lomefloxacin (0.1-1.0 mM; 24-72 h) decreases viability of COLO829 cells and induces ROS production in COLO829 cells[3].
Lomefloxacin (50-100 μM) induces apoptosis in keratinocyte[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:COLO829 melanoma cells
-
Concentration:0.0001, 0.001, 0.01, 0.05, 0.1, 0.5, 1.0 mM
-
Incubation Time:24, 48, 72 h
-
Result:Decreased cell viability by 12-68% at 0.1-1.0 mM for 24 h, with IC50 values of 0.51, 0.33, and 0.25 mM at 24, 48, 72 h, respectively.
Lomefloxacin (-80 mg/kg; orogastric administration) reduces mortality, significantly decreases splenic bacterial counts, and inhibits inflammatory response in mice infected with Salmonella typhimurium[5].
Lomefloxacin (16-32 mg/kg; i.p.; 5 days) only at the highest dose slightly reduces the number of implants and live fetuses in the third week of mating in mice, without significant dominant lethal mutation induction[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 98079-51-7
-
Appearance Solid
-
Molecular Weight 351.35
-
Formel C17H19F2N3O3
-
Color White to off-white
-
SMILES
O=C(C1=CN(CC)C2=C(C=C(F)C(N3CC(C)NCC3)=C2F)C1=O)O
-
Synonyms
SC47111A; NY-198
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 4 mg/mL (11.38 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (286 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Hirose T, et al. In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother. 1987 Jun;31(6):854-9. [Content Brief]
[2]. Piddock LJ, et al. Mechanism of action of lomefloxacin. Antimicrob Agents Chemother. 1990 Jun;34(6):1088-93. [Content Brief]
[3]. Beberok A, et al. Lomefloxacin Induces Oxidative Stress and Apoptosis in COLO829 Melanoma Cells. Int J Mol Sci. 2017 Oct 20;18(10):2194. [Content Brief]
[4]. Marrot L, et al. Molecular responses to photogenotoxic stress induced by the antibiotic lomefloxacin in human skin cells: from DNA damage to apoptosis. J Invest Dermatol. 2003 Sep;121(3):596-606. [Content Brief]
[5]. Butler T, et al. Treatment of experimental Salmonella typhimurium infection in mice with lomefloxacin. J Antimicrob Chemother. 1990 Apr;25(4):629-34. [Content Brief]
[6]. Singh AC, et al. Genotoxicity of lomefloxacin--an antibacterial drug in somatic and germ cells of Swiss albino mice in vivo. Mutat Res. 2003 Feb 5;535(1):35-42. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8462 mL | 14.2308 mL | 28.4616 mL | 71.1541 mL |
| 5 mM | 0.5692 mL | 2.8462 mL | 5.6923 mL | 14.2308 mL | |
| 10 mM | 0.2846 mL | 1.4231 mL | 2.8462 mL | 7.1154 mL |
Lomefloxacin Related Classifications
HY-B0455A Related Classifications
Powered by Bioz